Abstract
The mammalian target of rapamycin (mTOR), which assembles into two distinct multiprotein complexes, called mTORC1 and mTORC2, is known as a central regulator of cellular proliferation and maturation. Rictor is one of the key components of mTORC2 and acts as a scaffolding protein to maintain and stabilize mTORC2. Currently, mTORC2 and/or Rictor are increasingly being recognized as attractive targets for novel modalities of anti-cancer therapy. Unfortunately, the safety profile of Rictor- or mTORC2-targeting strategies has been poorly understood due to the lack of an ideal animal model. In the present study, we used zebrafish as an in vivo model system to evaluate the safety of Rictor inhibition. Our data showed that the Rictor of zebrafish was identified to have high sequence homology with mouse Rictor and human Rictor, which validates the rationale of using zebrafish as a research model. Rictor was dispensable in neonatal hematopoiesis and angiogenesis and was not required for vasculogenesis and other organs. These data are consistent with those of previous observations of using tissue-specific Rictor knockout mice model and have potentially important clinical implications. Our findings highlight a good in vivo safety profile for Rictor- or mTORC2-targeting therapy and point to the feasibility and advantages of using the zebrafish model to evaluate the safety of the therapeutic target.
Keywords: Rictor, zebrafish, target, inhibition.
Current Pharmaceutical Design
Title:Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Volume: 21 Issue: 12
Author(s): Yang Cao, Lijun Jiang, Lei Zhao, Xiaoxi Zhou, Na Wang, Peilin Zhang, Yuting Tang and Jianfeng Zhou
Affiliation:
Keywords: Rictor, zebrafish, target, inhibition.
Abstract: The mammalian target of rapamycin (mTOR), which assembles into two distinct multiprotein complexes, called mTORC1 and mTORC2, is known as a central regulator of cellular proliferation and maturation. Rictor is one of the key components of mTORC2 and acts as a scaffolding protein to maintain and stabilize mTORC2. Currently, mTORC2 and/or Rictor are increasingly being recognized as attractive targets for novel modalities of anti-cancer therapy. Unfortunately, the safety profile of Rictor- or mTORC2-targeting strategies has been poorly understood due to the lack of an ideal animal model. In the present study, we used zebrafish as an in vivo model system to evaluate the safety of Rictor inhibition. Our data showed that the Rictor of zebrafish was identified to have high sequence homology with mouse Rictor and human Rictor, which validates the rationale of using zebrafish as a research model. Rictor was dispensable in neonatal hematopoiesis and angiogenesis and was not required for vasculogenesis and other organs. These data are consistent with those of previous observations of using tissue-specific Rictor knockout mice model and have potentially important clinical implications. Our findings highlight a good in vivo safety profile for Rictor- or mTORC2-targeting therapy and point to the feasibility and advantages of using the zebrafish model to evaluate the safety of the therapeutic target.
Export Options
About this article
Cite this article as:
Cao Yang, Jiang Lijun, Zhao Lei, Zhou Xiaoxi, Wang Na, Zhang Peilin, Tang Yuting and Zhou Jianfeng, Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model, Current Pharmaceutical Design 2015; 21 (12) . https://dx.doi.org/10.2174/1381612821666150105120955
DOI https://dx.doi.org/10.2174/1381612821666150105120955 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts
Current Cancer Drug Targets LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design 3D-QSAR and Docking Studies of 4-morpholinopyrrolopyrimidine Derivatives as Potent mTOR Inhibitors
Letters in Drug Design & Discovery Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Systems Cytogenomics: Are We Ready Yet?
Current Genomics Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy